Floatz logo

Patritumab Deruxtecan

EGFR Exon 19 Deletion

Daiichi SankyoPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the EGFR Exon 19 Deletion cohort.

Asset / SponsorPhaseRating
Osimertinib
Peking Union Medical College Hospital
Phase 2BB

Same molecule, other indications

Patritumab Deruxtecan is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
breast neoplasmDormant
B
Indicative ·
60 / 100
View asset →
non-small cell squamous lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →